12:43 PM
 | 
Aug 31, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps for the humanized mAb against myostatin (MSTN; GDF8), which it had believed was a potential blockbuster.

In the double-blind, international Phase II B5161002 trial evaluating safety and efficacy, domagrozumab showed no significant improvement compared with placebo on the mean change from baseline to one year on a four-stair climb test, missing its primary endpoint. Pfizer said evaluation of all available data, including secondary endpoint results, did not suggest a...

Read the full 499 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >